In a bold move to deepen its footprint in rare disease treatment, Novo Nordisk SA announced Wednesday that it will acquire global rights to a promising antibody from U.S.-based Omeros Corp. in a licensing deal worth up to $2.1 billion.

The Danish pharmaceutical giant said the agreement covers zaltenibart, a clinical-stage antibody therapy targeting immune system dysregulation that can trigger severe blood and kidney disorders. Novo Nordisk will pay $340 million upfront, with additional milestone payments and royalties that could bring the total deal value to $2.1 billion.

The transaction marks another high-stakes bet by Novo Nordisk, already a titan in diabetes and obesity treatment, as it aims to diversify its pipeline with rare and specialized therapeutics.

A Strategic Partnership to Unlock Rare Disease Potential

Under the definitive asset purchase and license agreement, Novo Nordisk will hold exclusive global rights to develop and commercialize zaltenibart. Omeros, a Seattle-based biopharma known for small-molecule and protein-based therapies, will retain rights to its preclinical programs unrelated to zaltenibart.

Zaltenibart, designed to inhibit a specific immune-regulating protein, has already demonstrated encouraging Phase 2 results in a rare blood disorder where the immune system attacks red blood cells. Novo Nordisk plans to launch a Phase 3 trial following the deal’s close, testing the drug’s potential against a wider range of immune-driven kidney and blood diseases.

“This agreement builds on Omeros’ pioneering work and allows us to fully realize zaltenibart’s potential,”
said Martin Holst Lange, Novo Nordisk’s executive vice president for research and development.

Omeros Stands to Gain From Milestone-Driven Structure

For Omeros Corp., the deal represents both validation and opportunity. Its chairman and CEO Gregory Demopulos praised Novo Nordisk’s “global reach and deep expertise,” saying it could help bring the therapy to patients faster.

Omeros will receive royalties tied to the drug’s commercial success, and milestone payments as the antibody advances through clinical stages and regulatory approval.

The deal underscores a growing trend in biopharma, where large-cap firms increasingly license cutting-edge therapies from smaller innovators to accelerate their entry into emerging markets like rare disease immunology.

Closing Expected by End of 2025

While counsel information for the transaction was not immediately available, Novo Nordisk confirmed that the agreement is subject to regulatory approval. The company expects to finalize the deal by late 2025.

If approved, zaltenibart could become a cornerstone of Novo Nordisk’s rare disease franchise — a field poised to redefine modern immunotherapy by targeting the body’s most elusive disorders at the molecular level.

With its $2.1 billion bet, Novo Nordisk signals that its ambitions reach well beyond metabolic disease — into the realm of precision medicine and immunological innovation.